These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36108960)

  • 1. Programmatic management of rifampicin-resistant tuberculosis with standard regimen in Cameroon: a retrospective cohort study.
    Jouego CG; Gils T; Piubello A; Mbassa V; Kuate A; Ngono A; Belinga E; Etoundi A; Tollo A; Makondi D; André E; Masumbe P; Lynen L; Noeske J; Decroo T
    Int J Infect Dis; 2022 Nov; 124():81-88. PubMed ID: 36108960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Prior Tuberculosis Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis.
    Mikiashvili L; Kempker RR; Chakhaia TS; Bablishvili N; Avaliani Z; Lomtadze N; Schechter MC; Kipiani M
    Clin Infect Dis; 2024 Apr; 78(4):1043-1052. PubMed ID: 37962987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
    Ndjeka N; Campbell JR; Meintjes G; Maartens G; Schaaf HS; Hughes J; Padanilam X; Reuter A; Romero R; Ismail F; Enwerem M; Ferreira H; Conradie F; Naidoo K; Menzies D
    Lancet Infect Dis; 2022 Jul; 22(7):1042-1051. PubMed ID: 35512718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translating drug resistant tuberculosis treatment guidelines to reality in war-torn Kandahar, Afghanistan: A retrospective cohort study.
    Mesic A; Khan WH; Lenglet A; Lynen L; Ishaq S; Phyu EHH; Mar HT; Oraegbu A; Seddiq MK; Amirzada HK; Fernhout J; Kamau C; Ariti C; Gomez D; Decroo T
    PLoS One; 2020; 15(8):e0237787. PubMed ID: 32822375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study.
    Souleymane MB; Decroo T; Mamadou S; Soumana A; Lawan IM; Gagara-Issoufou A; Adehossi E; Ortuño-Gutiérrez N; Lynen L; Rigouts L; de Jong BC; Van Deun A; Piubello A
    Int Health; 2023 May; 15(3):258-264. PubMed ID: 35420123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Rifampicin-Resistant Tuberculosis Mortality among HIV-Coinfected Patients in Rwanda.
    Habimana DS; Ngabonziza JCS; Migambi P; Mucyo-Habimana Y; Mutembayire G; Byukusenge F; Habiyambere I; Remera E; Mugwaneza P; Mwikarago IE; Mazarati JB; Turate I; Nsanzimana S; Decroo T; de Jong CB
    Am J Trop Med Hyg; 2021 May; 105(1):47-53. PubMed ID: 33999845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study).
    Esmail A; Oelofse S; Lombard C; Perumal R; Mbuthini L; Goolam Mahomed A; Variava E; Black J; Oluboyo P; Gwentshu N; Ngam E; Ackerman T; Marais L; Mottay L; Meier S; Pooran A; Tomasicchio M; Te Riele J; Derendinger B; Ndjeka N; Maartens G; Warren R; Martinson N; Dheda K
    Am J Respir Crit Care Med; 2022 May; 205(10):1214-1227. PubMed ID: 35175905
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of Multidrug-resistant or Rifampicin-resistant Tuberculosis With an All-oral 9-month Regimen Containing Linezolid or Ethionamide in South Africa: A Retrospective Cohort Study.
    Morgan H; Ndjeka N; Hasan T; Gegia M; Mirzayev F; Nguyen LN; Schumacher S; Schlub TE; Naidoo K; Fox GJ
    Clin Infect Dis; 2024 Jun; 78(6):1698-1706. PubMed ID: 38525535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence-based Definition for Extensively Drug-Resistant Tuberculosis.
    Roelens M; Battista Migliori G; Rozanova L; Estill J; Campbell JR; Cegielski JP; Tiberi S; Palmero D; Fox GJ; Guglielmetti L; Sotgiu G; Brust JCM; Bang D; Lienhardt C; Lange C; Menzies D; Keiser O; Raviglione M
    Am J Respir Crit Care Med; 2021 Sep; 204(6):713-722. PubMed ID: 34107231
    [No Abstract]   [Full Text] [Related]  

  • 10. A four-drug standardized short regimen for highly resistant TB in South-West Nigeria.
    Fadeyi MO; Decroo T; Ortuño-Gutiérrez N; Ahmed B; Jinadu A; El-Tayeb O; Adebola W; Kehinde A; Lynen L; Gils T
    Int Health; 2024 Jan; 16(1):123-125. PubMed ID: 37026448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.
    Chiang CY; Lin CJ
    Indian J Tuberc; 2020 Dec; 67(4S):S16-S22. PubMed ID: 33308663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: Nationwide programmatic achievements.
    Piubello A; Souleymane MB; Hassane-Harouna S; Yacouba A; Lempens P; Assao-Neino MM; Maman-Lawan I; Attaher S; Moustapha B; Soumana A; Gagara-Issoufou A; Ortuño-Gutiérrez N; Roggi A; Gumusboga M; Hamidou-Harouna Z; Dockx J; Mamadou S; de Jong BC; Decroo T; Van Deun A
    Respir Med; 2020 Jan; 161():105844. PubMed ID: 32056722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug-resistant pulmonary tuberculosis at Maradi Regional Hospital Center, Niger (2014-2018)].
    Harouna Amadou ML; Maman Lawan I; Abdoulaye O; Ibrahim Mamadou AK; Amadou O; Boureima H; Ahamadou B; Hama Aghali N; Abdourahamane Maifada NH; Kabirou Amoussa A; Maidakouale C
    Med Trop Sante Int; 2023 Dec; 3(4):. PubMed ID: 38390008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis.
    Tack I; Dumicho A; Ohler L; Shigayeva A; Bulti AB; White K; Mbatha M; Furin J; Isaakidis P
    Clin Infect Dis; 2021 Nov; 73(9):e3563-e3571. PubMed ID: 33372989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High mortality among patients hospitalized for drug-resistant tuberculosis with acquired second-line drug resistance and high HIV prevalence.
    Anderson K; Pietersen E; Shepherd BE; Bian A; Dheda K; Warren R; Sterling TR; van der Heijden YF
    HIV Med; 2022 Nov; 23(10):1085-1097. PubMed ID: 35608016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
    Park S; Jo KW; Lee SD; Kim WS; Shim TS
    Respir Med; 2017 Oct; 131():43-48. PubMed ID: 28947041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward.
    Van Deun A; Decroo T; Tahseen S; Trébucq A; Schwoebel V; Ortuno-Gutierrez N; de Jong BC; Rieder HL; Piubello A; Chiang CY
    Int J Antimicrob Agents; 2020 Jan; 55(1):105822. PubMed ID: 31626907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early mortality during rifampicin-resistant TB treatment.
    Mohr-Holland E; Daniels J; Reuter A; Rodriguez CA; Mitnick C; Kock Y; Cox V; Furin J; Cox H
    Int J Tuberc Lung Dis; 2022 Feb; 26(2):150-157. PubMed ID: 35086627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early results of systematic drug susceptibility testing in pulmonary tuberculosis retreatment cases in Cameroon.
    Noeske J; Voelz N; Fon E; Abena Foe JL
    BMC Res Notes; 2012 Mar; 5():160. PubMed ID: 22436423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of pulmonary MDR-TB: impacts of fluoroquinolone resistance and linezolid treatment.
    Jeong BH; Jeon K; Park HY; Kwon OJ; Lee KS; Kim HK; Choi YS; Kim J; Huh HJ; Lee NY; Koh WJ
    J Antimicrob Chemother; 2015 Nov; 70(11):3127-33. PubMed ID: 26203184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.